Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

This is a multicenter, open Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of BEBT-109 combined with injectable pemetrexed disodium and carboplatin or cisplatin injection as first-line treatment for locally advanced, recurrent, or metastatic non-small cell lung cancer carrying EGFR exon 20 insertion mutations.

NCT Number	NCT06514027
Lead Sponsor	BeBetter Med Inc
Conditions	Non Small Cell Lung Cancer
Enrollment	30 participants
Start Date	2024-07
Primary Completion	2027-06 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2024-07-23